1. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013; 10: 686-690.
2.
Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-438.
3.
Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? J Hepatol 2018; 68: 335-352.
4.
Byrne CD, Olufadi R, Bruce KD, et al. Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond) 2009; 116: 539-564.
5.
Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med 2018; 24: 908-922.
6.
Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet 2021; 397: 2212-2224.
7.
Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015; 62 (1 Suppl): S47-S64.
8.
Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020; 158: 1999-2014.e1.
9.
Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature [published online ahead of print, 2023 Jun 24]. Hepatology 2023; 10.1097/HEP.0000000000000520.
10.
Cheng YM, Wang CC, Kao JH. Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications. Hepatol Int 2023; 17: 350-356.
11.
Yamamura S, Eslam M, Kawaguchi T, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int 2020; 40: 3018-3030.
12.
Yu C, Wang M, Zheng S, et al. Comparing the diagnostic criteria of MAFLD and NAFLD in the Chinese population: A population-based prospective cohort study. J Clin Transl Hepatol 2022; 10: 6-16.
13.
Fan CT, Lin JC, Lee CH. Taiwan Biobank: A project aiming to aid Taiwan’s transition into a biomedical island. Pharmacogenomics 2008; 9: 235-246.
14.
Lin JC, Fan CT, Liao CC, Chen YS. Taiwan biobank: Making cross-database convergence possible in the big data era. Gigascience 2018; 7: 1-4.
15.
Wijarnpreecha K, Aby ES, Panjawatanan P, et al. Modest alcohol consumption and risk of advanced liver fibrosis in nonalcoholic fatty liver disease: A systematic review and meta-analysis. Ann Gastroenterol 2021; 34: 568-574.
16.
Jarvis H, O’Keefe H, Craig D, et al. Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis. BMJ Open 2022; 12: e049767.
17.
Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6: 33.
18.
Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-854.
19.
Kabłak-Ziembicka A, Przewłocki T. Clinical significance of carotid intima-media complex and carotid plaque assessment by ultrasound for the prediction of adverse cardiovascular events in primary and secondary care patients. J Clin Med 2021; 10: 4628.
20.
De A, Bhagat N, Mehta M, et al. Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol 2024; 80: e61-e62.
21.
Wang CC, Cheng YM, Kao JH. Letter to the Editor: Statement of steatotic liver disease: A great leap towards the global standardization. Hepatology 2024; 79: E7-E8.
22.
Rockey DC, Caldwell SH, Goodman ZD, et al.; American Association for the Study of Liver Diseases. Liver biopsy. Hepatology 2009; 49: 1017-1044.
23.
Dasarathy S, Dasarathy J, Khiyami A, et al. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol 2009; 51: 1061-1067.
Copyright: © Clinical and Experimental Hepatology. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/) enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
